ATOS
ATOSSA THERAPEUTICS, INC.Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsMIXED
Q2 2026: 1 added (0 new), 2 trimmed or exited.
- AnalystsBULLISH
7 of 8 rate it Buy or better.
- EstimatesRISING
Current-quarter EPS estimate −$1.100 → −$0.780 over 90 days. 1 up, 0 down in 30 days.
- Short sellersSTEADY
Short interest −13.3% to 683.5K shares. 5.8 days to cover, ≈6.8% of shares.
- TrendRANGE
3% below its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Oct 17.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| MILLENNIUM MANAGEMENT LLC | TRIM | $89.8K |
| ROYAL BANK OF CANADA | DOUBLED | $4.0K |
| GROUP ONE TRADING LLC | NEAR_EXIT | $104.00 |
| CWM, LLC | NEAR_EXIT | — |
| AMERIPRISE FINANCIAL INC | ADD | $2.2M |
| RENAISSANCE TECHNOLOGIES LLC | ADD | $1.2M |
| MILLENNIUM MANAGEMENT LLC | TRIM | $733.3K |
| STATE STREET CORP | ADD | $351.9K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
8 analysts| Date | Firm | Rating |
|---|---|---|
| Oct 1, 2026 | Ascendiant Capital MAINTAIN | Buy |
| Jul 7, 2026 | Rodman & Renshaw INITIATE | Buy |
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| May 12, 2026 | Cigler Tessa Director | AWARD | 10,000 sh |
| May 12, 2026 | Galli Stephen J Director | AWARD | 10,000 sh |
| May 12, 2026 | Finn Jonathan Director | AWARD | 10,000 sh |
| May 12, 2026 | Remmel H. Lawrence Director | AWARD | 10,000 sh |
| May 12, 2026 | Chen Shu-Chih Director | AWARD | 10,000 sh |
| May 12, 2026 | Steinhart Richard I Director | AWARD | 10,000 sh |
| Mar 27, 2026 | QUAY STEVEN C President & CEO | AWARD | 65,000 sh |
| Mar 26, 2026 | Daniel Mark James Chief Financial Officer | AWARD | 63,000 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.78 | -$0.78–-$0.78 | +29.1% | $0.00 |
| Next Q | -$0.78 | -$0.78–-$0.78 | +29.1% | $0.00 |
| Current FY | -$3.56 | -$3.56–-$3.56 | +19.1% | $0.00 |
| Next FY | -$3.30 | -$3.30–-$3.30 | +24.7% | $0.00 |
Short side
FINRA· Oct 15, 2026SecBot reports
7 filings · 1 bullish · 1 bearish · 5 neutral- NEUTRAL 8-KOct 9, 2026
Atossa Therapeutics entered into a Contingent Value Rights (CVR) Agreement, declaring a dividend…
Monitor Atossa's regulatory progress on (Z)-endoxifen for Duchenne muscular dystrophy and McCune-Albright syndrome — FDA approval of a qualifying marketing application is the prerequisite for any…
- NEUTRAL 8-KSep 29, 2026
Atossa Therapeutics announced a plan to issue one contingent value right (CVR) per share of common…
The CVR creates a potential catalyst path tied to rare pediatric disease voucher monetization, but with no approved product or awarded voucher, this is a long-dated, binary event. Monitor…
- NEUTRAL 8-KSep 18, 2026
Atossa Therapeutics filed an 8-K on September 18, 2026, to make available an updated corporate…
Monitor EVANGELINE Phase 2 top-line data expected in 4Q26 and IND clearance for MAS/DMD programs in 2H26 as key near-term catalysts. Cash runway into 2027 provides no immediate financing urgency.
- NEUTRAL 8-KAug 7, 2026
Atossa Therapeutics reported Q2 2026 net loss of $8.5M ($0.95 per share), beating consensus of…
Monitor cash runway: at current burn rate (~$7.6M/quarter), cash plus upfront offering proceeds provide roughly 4 quarters of funding before additional capital is needed. Watch for clinical data…
All ATOS filing & press-release reports (7)
- 8-K reportOct 9, 2026
- 8-K reportSep 29, 2026
- 8-K reportSep 18, 2026
- PRESS-RELEASE reportAug 7, 2026
- 8-K reportAug 7, 2026
- 424B5 reportJun 12, 2026
- 8-K reportApr 16, 2026